Gina Ortiz
Family · Berlin, NJNPI 1942480462
Payments from drug & device makers
Across 440 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- Pfizer$664
- GSK$585
- Novo Nordisk$484
- Otsuka America Pharmaceutical, Inc.$290
- plus $2K from 38 others
What the payments were for
- Food & beverage$6,59299%
- Education$611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,653 in reported general payments places this provider in the 95th percentile of 2,692 family providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $55,381 |
| FarxigaDapagliflozin Propanediol | 42 | $30,184 |
| EliquisApixaban | 26 | $26,185 |
| JardianceEmpagliflozin | 16 | $14,750 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $12,308 |
| VascepaIcosapent Ethyl | 24 | $8,444 |
| BelsomraSuvorexant | 12 | $4,766 |
| Icosapent Ethyl | 14 | $3,663 |
| Bupropion XlBupropion Hcl | 46 | $2,192 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 63 | $1,890 |
| Omega-3 Acid Ethyl Esters | 11 | $1,790 |
| Oxycodone Hcl | 54 | $1,775 |
| Rosuvastatin Calcium | 127 | $1,561 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 32 | $1,479 |
| Pantoprazole Sodium | 92 | $1,289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $484 | $55,38154 claims |
| AstraZenecaFarxiga | $1,118 | $30,18442 claims |
| PfizerEliquis | $664 | $26,18526 claims |
| Boehringer IngelheimJardiance | $172 | $14,75016 claims |
| GSKTrelegy Ellipta | $585 | $12,30812 claims |
| MerckBelsomra | $87 | $4,76612 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $146 | $52913 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $17 | $51419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,692 family providers in New Jersey.
Other family in Berlin
- Jennifer DemaioMorristown$412K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- Angie GarciaWest New York$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Megan FiloramoMorristown$53K
- Shawn DenningToms River$29K
- Kimberly ClementeEatontown$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.